Fig. 1: Schematic of the DMAb technology platform. | Nature Medicine

Fig. 1: Schematic of the DMAb technology platform.

From: Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial

Fig. 1

a, Four synthetic DNA constructs were designed for optimal in vivo expression of the HCs and light chains (LCs) of AZD5396 and AZD8076. Designs were based on the parental mAb clones COV2-2130 (2130) and COV2-2196 (2196), the precursors of AZD7442, respectively. pAZD5396 and pAZD8076 LC and HC synthetic DNA construct cocktails were each formulated with the human recombinant hyaluronidase enzyme. b, pAZD5396 and pAZD8076 were administered separately with in vivo EP for the local expression of the transgenes in the deltoid muscle. DMAbs are expressed in the myocytes and secreted into the circulation. c, CELLECTRA EP delivery system for enhanced local transgene expression. The EP electrical field parameters and injected fluid distribution have been optimized to align to permit enhanced transgene expression in the muscle (shown as green fluorescent protein reporter gene expression in New Zealand rabbit muscle). Expressed transgenes, such as DMAbs, can be measured in the serum of the recipient. Illustrations in a and b created using BioRender.com. CMV, cytomegalovirus.

Back to article page